drugset / Trial / NCT00998738

Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

NCT00998738

RandomizedParallel-groupDouble-blindSupportive care

Summary

This randomized phase III trial studies calcium and magnesium to see how well they work in preventing peripheral neuropathy caused by ixabepilone in patients with breast cancer. Giving calcium together with magnesium may stop or delay the development of peripheral neuropathy in patients with cancer who are receiving treatment with ixabepilone. It is not yet known whether calcium and magnesium are effective in preventing peripheral neuropathy caused by ixabepilone.

Timeline

Start
2009-11
Primary completion
2010-07
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified
Subject calcium gluconate Small molecule
Background Ixabepilone Small molecule